CD5 and myeloid sarcoma: Indeed, in MS, where demyelination and aggressive disease progression are associated with the presence of T cells (211), exploiting this immunoregulatory subset of IL-10 secreting CD5+ B cells to dampen neuroinflammation remains a current research focus (Figure 4).